Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
Active, not recruiting · NCT06300528 · Registry updated 2026-07-09Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas | B-cell neoplasm, Disease Attributes, Hemic and Lymphatic Diseases, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, marginal zone lymphoma, neoplasm | Active, not recruiting | Phase 2 | 2026-07-09 | NCT06300528 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Incyte Corporation | 153 |
| University of Utah | 319 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Huntsman Cancer Institute at University of Utah | Salt Lake City | United States | 28 |